The National Women and Girls HIV/AIDS Awareness Day started on March 10, 2005. This day highlights the impact HIV and AIDS has on women and girls, and ongoing efforts to reduce HIV and AIDS among women and girls in the United States.
The NIH Office of AIDS Research (OAR) and Office of Research on Women’s Health (ORWH) co-sponsored the NIH OAR-ORWH Women & HIV Symposium: Considerations from Across the Lifespan during the 13th International Workshop on HIV & Women 2023 in Seattle, Washington.
The Panel on Treatment of HIV in Pregnancy and Prevention of Perinatal Transmission (the Panel) updated the Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States.
The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (or the Panel) is accepting applications for new scientific/clinical members with expertise in HIV medicine.
The Panel on Opportunistic Infections in Adults and Adolescents (the Panel) updated the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV.
The Clinicalinfo mobile application, which was originally created to provide mobile access to the resources now available on the optimized website, will sunset on December 30, 2022.
The event will be broadcast live via NIH Videocast on Thursday, December 1, 2022, from 1:00 to 2:30 p.m. ET.
Join a distinguished group of participants for a live discussion as NIH marks the global World AIDS Day observance.
Please save the date for the NIH World AIDS Day 2022 Virtual Event: Progress and Promise in HIV Research.
The HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (or the Panel) is accepting nominations for new scientific/clinical members with expertise in HIV medicine.
National Latinx AIDS Awareness Day (NLAAD) is a day to raise awareness about the impact of HIV on the Hispanic/Latino communities in the United States.
The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) has made revisions to address U.S. Food and Drug Administration approval of the dispersible tablet formulation of the fixed-dose combination abacavir/dolutegravir/lamivudine (Triumeq PD) for use in children weighing 10 kg to 25 kg and the long-acting injectable cabotegravir and rilpivirine (Cabenuva) for use in children and adolescents aged ≥12 years and weighing ≥35 kg.
The Panel on Opportunistic Infections in Adults and Adolescents (the Panel) updated the monkeypox section of the guidelines.
September 27 is National Gay Men’s HIV/AIDS Awareness Day. The annual observance is held each year to focus attention on the disproportionate impact of HIV and AIDS on gay and bisexual men.
The National Institutes of Health (NIH) Office of AIDS Research (OAR) joined the world's largest gathering on HIV/AIDS at the 24th International AIDS Conference (AIDS 2022).
The Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) updated several sections of the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.